Insilico Medicine, a global AI-driven biotech firm, has submitted its Hong Kong Stock Exchange (HKEX) listing application with Morgan Stanley, CICC and GF Securities as joint sponsors, following its USD 100 million Series E funding round in February 2025 that valued the company at USD 1.33 billion. The company’s lead asset, ISM001-055 (rentosertib), a selective TNIK inhibitor for idiopathic pulmonary fibrosis (IPF), completed Phase IIa trials in China in 2024 with topline data showing promise, and holds both FDA orphan drug designation and China’s breakthrough therapy status. Insilico’s proprietary Pharma.AI platform — which reduced drug discovery timelines to 18 months for novel targets — has generated over 20 clinical/IND-stage assets, including three licensed to multinationals for over USD 2 billion. Revenue grew from USD 30.2 million in 2022 to USD 85.8 million in 2024, primarily from drug discovery partnerships with firms like Fosun Pharma and Sanofi. Proceeds will fund late-stage trials, AI model development and lab expansion, bolstering its dual-engine model combining AI and in-house R&D. Founded in 2014 by CEO Dr. Alex Zhavoronkov, the company holds 644 patents and expands its AI applications into materials science and agriculture.